Akron Biotech

Akron Biotech PELOBiotech GmbH

Akron Biotech is an expert in cGMP products (Recombinant proteins, human Fibronectin, and human plasma-derived products).

Akron Biotech offers a wide variety of cell culture tools such as recombinant proteins, human plasma-derived products (such as AB-serum, HAS and insulin), cryo-media and custom media and media supplements which are available in research and GMP quality.

At Akron you can also find high-quality and cGMP-compliant plasmid DNA for pre-clinical all the way to commercial gene therapy.

Filter products

Akron Biotech PELOBiotech GmbH

Recombinant human interleukin-2 (rhu il-2) closed system solutionstm (css), 1 miu

Supplier
Akron Biotech

Catalog Number
PB-AR1045-0010

Akron Biotech PELOBiotech GmbH

Recombinant human interleukin-2 (rhu il-2) closed system solutionstm (css), 15 miu

Supplier
Akron Biotech

Catalog Number
PB-AR1050-0020

Akron Biotech PELOBiotech GmbH

Recombinant human interleukin 12 (rhu il-12), (cgmp)

Supplier
Akron Biotech

Catalog Number
PB-AR1051-0100

Akron Biotech PELOBiotech GmbH

Recombinant human interleukin 12 (rhu il-12),(cgmp)

Supplier
Akron Biotech

Catalog Number
PB-AR1051-0200

Akron Biotech PELOBiotech GmbH

Recombinant human interleukin 18 (rhu il-18), (cgmp)

Supplier
Akron Biotech

Catalog Number
PB-AR1052-0050

Akron Biotech PELOBiotech GmbH

Recombinant human interleukin 18 (rhu il-18), (cgmp)

Supplier
Akron Biotech

Catalog Number
PB-AR1052-0100

Akron Biotech PELOBiotech GmbH

Recombinant human interleukin-15 (rhu il-15) closed system solutionstm (css), 0,5 miu/bag

Supplier
Akron Biotech

Catalog Number
PB-AR1003-0050

Akron Biotech PELOBiotech GmbH

Recombinant human interleukin-7 (rhu il-7) closed system solutionstm (css), 5 miu/bag

Supplier
Akron Biotech

Catalog Number
PB-AR1013-0050

Akron Biotech PELOBiotech GmbH

Recombinant human interleukin-2 (rhu il-2) closed system solutionstm (css), 2 miu

Supplier
Akron Biotech

Catalog Number
PB-AR1045-0020

Akron Biotech PELOBiotech GmbH

Rhu il-12

Supplier
Akron Biotech

Catalog Number
PB-AK9995-0020

Akron Biotech PELOBiotech GmbH

Rhu il-12

Supplier
Akron Biotech

Catalog Number
PB-AK9995-0100

Akron Biotech PELOBiotech GmbH

Rhu il-18

Supplier
Akron Biotech

Catalog Number
PB-AK9999-0025

cGMP Recombinant Proteins.

Akron's high-quality cGMP recombinant proteins provide the consistency, safety and efficacy required by today's leading clinical and commercial cell therapy companies.

Cytokines, Chemokines, Growth Factors and more

The result is recombinant proteins with exceptional characterization, purity and consistency from batch to batch. Akron uses robust pharmaceutical grade purification strategies (IEX/SEC/TTF) and always adheres to international standards and guidelines when available. Starting from Albumin to rHu TNF-alpha in cGMP-quality you´ll find these proteins in the section GMP proteins.

Our GMP proteins

cGMP Cell Culture Tools/ Human Plasma Derived Products

Optimal growth and viability within cGMP guidelines

Akron Bio developed its human plasma-derived products and cell culture tools to provide optimal cell growth and viability within cGMP manufacturing guidelines. Each product undergoes rigorous quality control with particular emphasis on safety and batch-to-batch consistency. These materials—including virus-inactivated human fibronectin, Human AB Serum converted from Octaplas®, and Human Serum Albumin 25% solution—are supported by comprehensive manufacturing documentation and pathogen safety data designed to meet regulatory requirements of leading health authorities in the US, EU, and Asia. All products are backed by Type II Drug Master Files on file with the FDA and have received eligibility confirmation from Japan's PMDA for clinical use. The complete portfolio is available in both traditional formats and the innovative Closed System Solutions™ line, enabling seamless integration into automated cell and gene therapy manufacturing workflows. You´ll find these products in the section Cell Culture Tools.

Our Cell culture tools

Akron Biotech PELOBiotech GmbH

cGMP Cell Culture Media & Cryo Preservation

Akron offers Cryo-Preservation in cGMP and high-quality research grade. To name one here…

CryoSolutions™ 100% product is cGMP conform.

The formulation contains sterile, filtered DMSO (Dimethyl Sulfoxide, USP/EP), highest purity grade >99.99%. Post-thaw viability is comparable or superior to the leading DMSO-containing cryomedia. Sterility and Bacterial Endotoxin testing are performed per USP/EP on the final product. Media is packaged in glass vials and available in a 100 mL aliquot. Akron’s cGMP-compliant CryoSolutions™ 100% is intended for the cryo-preservation of biological cells in cell culture, stem cells, mammalian cells and biological tissues.

And there's more you might also like to check out... rHu IL-2 (cGMP)

Akron Biotech rHu IL-2 (cGMP)

Facts about Akron. References.

Burke CJ, Zylberberg C. Sources of Variability in Manufacturing of Cell Therapies. Regenerative Engineering and Translational Medicine, 2019, DOI 10.1007/s40883-019-00130-5

Nathan D. Frank, Ezequiel Zylberberg, Mahajoub Bello Roufai, Stuart L. Gibb, and Mindy M. Miller. Good Manufacturing Practice-Grade Fibronectin for Hollow-Fiber Bioreactor Cell Manufacture: A Mesenchymal Stromal Cell Case Study. Cytotherapy, December 6, 2024.

Jonian Grosha, Jun-Hung Cho, Shannon Pasley, Peter Kilbride, Claudia Zylberberg, and Marsha W. Rolle Engineered Test Tissues: A Model for Quantifying the Effects of Cryopreservation Parameters. ACS Biomaterials Science & Engineering, October 6, 2023, DOI: 10.1021/acsbiomaterials.3c00752

Burke CJ, Zylberberg C. Sources of Variability in Manufacturing of Cell Therapies. Regenerative Engineering and Translational Medicine, 2019, DOI 10.1007/s40883-019-00130-5

Harrison RP, Zylberberg E, Ellison S, Levine BL. Chimeric antigen receptor–T cell therapy manufacturing: modelling the effect of offshore production on aggregate cost of goods. Cytotherapy, 2019, In Press.

El Assal, L. Abou‐Elkacem, A. Tocchio, S. Pasley, S. Matosevic, D. L. Kaplan, C. Zylberberg, U. Demirci. Bioinspired Preservation of Natural Killer Cells for Cancer Immunotherapy. Adv. Sci.2019, 1802045.

Bruce CJ, Guojun B, Centanni JM, Davis MD, Dobson J, Hare JM, Fields GB, Jove R, Kenyon N, Kahn A, March K, Matosevic S, Mahmood A, Pepine CJ, Ricordi C, Shapiro SA, Zylberberg C, Zylberberg E. Regenerative Medicine in the State of Florida: Letter Outlining the Florida Organization for Regenerative Medicine. Stem Cells Translational Medicine, 2018, 7(7): 511-512.

National Academies of Sciences, Engineering, and Medicine. 2017. Navigating the Manufacturing Process and Ensuring the Quality of Regenerative Medicine Therapies: Proceedings of a Workshop. Washington, DC: The National Academies Press.

Zylberberg C and Matosevic S. Bioengineered liposome-scaffold composites as therapeutic delivery systems. Therapeutic Delivery, 2017, 8(6):425-445.

Zylberberg C, Gaskill K, Pasley S, Matosevic S. Engineering liposomal nanoparticles for targeted gene therapy. Gene Therapy, 2017, 24(8):441-452.

Haddock R, Lin-Gibson S, Lumelsky N, McFarland R, Roy K, Saha K, Zhang J, Zylberberg C. Manufacturing Cell Therapies: The Paradigm Shift in Health Care of This Century. 2017, National Academy of Medicine, 1-13.

Buckler L, Kunkel E, Thompson M, Ehrhardt R. Technological developments for small-scale downstream processing of cell therapies. 2016, Cytotherapy, 18(3):301-306.

MForesight: Alliance for Manufacturing Foresight. Biomanufacturing Technologies for Regenerative Medicine. 2016.

Zylberberg C, Matosevic S. Pharmaceutical liposomal drug delivery: a review of new delivery systems and a look at the regulatory landscape. 2016, Drug delivery, 23(9):3319-3329.

Solomon J, Csontos L, Clarke D, Bonvhadi M, Zylberberg C, McNiece I, Kurtzberg J, Bell R, Deans R. Current perspectives on the use of ancillary materials for the manufacture of cellular therapies. 2016, Cytotherapy, 18(1):1-12.

Knapinska A, Amar S, He Z, Matosevic S, Zylberberg C, Fields G. Matrix metalloproteinases as reagents for cell isolation. Enzyme and Microbial Technology, 2016, 93-94:29-43.

Porat Y, Abraham E, O Karnieli, Nahum S, Woda J, Zylberberg C. Critical elements in the development of cell therapy potency assays for ischemic conditions. 2015, Cytotherapy, 17(7):817-831.

Abbott S, MacKay G, Durdy M, Solomon S, Zylberberg C. Twenty years of the International Society for Cellular Therapies: the past, present and future of cellular therapy clinical development. 2014, Cytotherapy, 16(4):S112-S119.

Assal RE, Guven S, Gurkan UA, et al. Bio-inspired Cryo-ink Preserves Red Blood Cell Phenotype and Function during Nanoliter Vitrification. 2014, Advanced materials, 26(33):5815-5822.

 

El Assal, L. Abou‐Elkacem, A. Tocchio, S. Pasley, S. Matosevic, D. L. Kaplan, C. Zylberberg, U. Demirci. Bioinspired Preservation of Natural Killer Cells for Cancer Immunotherapy. Adv. Sci.2019, 1802045.

Bruce CJ, Guojun B, Centanni JM, Davis MD, Dobson J, Hare JM, Fields GB, Jove R, Kenyon N, Kahn A, March K, Matosevic S, Mahmood A, Pepine CJ, Ricordi C, Shapiro SA, Zylberberg C, Zylberberg E. Regenerative Medicine in the State of Florida: Letter Outlining the Florida Organization for Regenerative Medicine. Stem Cells Translational Medicine, 2018, 7(7): 511-512.

National Academies of Sciences, Engineering, and Medicine. 2017. Navigating the Manufacturing Process and Ensuring the Quality of Regenerative Medicine Therapies: Proceedings of a Workshop. Washington, DC: The National Academies Press.

Zylberberg C and Matosevic S. Bioengineered liposome-scaffold composites as therapeutic delivery systems. Therapeutic Delivery, 2017, 8(6):425-445.

Zylberberg C, Gaskill K, Pasley S, Matosevic S. Engineering liposomal nanoparticles for targeted gene therapy. Gene Therapy, 2017, 24(8):441-452.

Haddock R, Lin-Gibson S, Lumelsky N, McFarland R, Roy K, Saha K, Zhang J, Zylberberg C. Manufacturing Cell Therapies: The Paradigm Shift in Health Care of This Century. 2017, National Academy of Medicine, 1-13.

Buckler L, Kunkel E, Thompson M, Ehrhardt R. Technological developments for small-scale downstream processing of cell therapies. 2016, Cytotherapy, 18(3):301-306.

MForesight: Alliance for Manufacturing Foresight. Biomanufacturing Technologies for Regenerative Medicine. 2016.

Solomon J, Csontos L, Clarke D, Bonvhadi M, Zylberberg C, McNiece I, Kurtzberg J, Bell R, Deans R. Current perspectives on the use of ancillary materials for the manufacture of cellular therapies. 2016, Cytotherapy, 18(1):1-12.

Knapinska A, Amar S, He Z, Matosevic S, Zylberberg C, Fields G. Matrix metalloproteinases as reagents for cell isolation. Enzyme and Microbial Technology, 2016, 93-94:29-43.

Porat Y, Abraham E, O Karnieli, Nahum S, Woda J, Zylberberg C. Critical elements in the development of cell therapy potency assays for ischemic conditions. 2015, Cytotherapy, 17(7):817-831.

Abbott S, MacKay G, Durdy M, Solomon S, Zylberberg C. Twenty years of the International Society for Cellular Therapies: the past, present and future of cellular therapy clinical development. 2014, Cytotherapy, 16(4):S112-S119.

Assal RE, Guven S, Gurkan UA, et al. Bio-inspired Cryo-ink Preserves Red Blood Cell Phenotype and Function during Nanoliter Vitrification. 2014, Advanced materials, 26(33):5815-5822.